NASDAQ:AURA Aura Biosciences Q3 2026 Earnings Results & Report $7.49 -0.17 (-2.27%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Aura Biosciences beat analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.29 versus the -$0.3681 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeBefore Market OpensConference Call7:00 AM ET Aura Biosciences EPS ResultsActual EPS-$0.29Consensus EPS -$0.3681Beat/MissBeat by +$0.0781One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersAura Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aura Biosciences Q3 2026 Earnings FAQ Did Aura Biosciences beat earnings estimates for Q3 2026? Aura Biosciences (NASDAQ:AURA) reported earnings of -$0.29 per share for Q3 2026, beating the consensus estimate of -$0.3681. The report was announced on Monday, November 9, 2026. Aura Biosciences Earnings HeadlinesAura Biosciences Advances Phase 3 Eye Cancer Trial; Cash Runway Extends Into 2029November 9 at 10:01 AM | rttnews.comAura Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 9 at 10:01 AM | marketscreener.comMThe Withdrawal You'll Never See on Your StatementA proposal circulating in Washington, dubbed the Mar-a-Lago Accord, calls for tariffs and currency pressure to deliberately weaken the US dollar, making American exports cheaper. For savers, a weaker dollar can quietly reduce purchasing power even if account balances stay the same. Bishop Gold Group's free 2026 Gold IRA Guide explains how physical gold can be held inside a retirement account, including a common rollover mistake that can trigger a taxable distribution.November 10 at 1:00 AM | Bishop Gold Group (Ad)Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business HighlightsNovember 9 at 10:01 AM | markets.businessinsider.comAura Biosciences to Participate in Upcoming Investor ConferenceNovember 3, 2026 | globenewswire.comAura Biosciences: A Pivotal Trial Engineered With Room To SpareOctober 31, 2026 | seekingalpha.comSee More Aura Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email. Email Address About Aura BiosciencesAura Biosciences (NASDAQ:AURA) (NASDAQ:AURA) is a clinical-stage biotechnology company developing targeted therapies for cancer. The company’s platform is designed to use tumor-targeting virus-like particles to selectively bind to cancer cells and deliver therapeutic payloads, with the goal of treating tumors while limiting damage to surrounding healthy tissue. Aura’s lead product candidate is AU-011, also known as belzupacap sarotalocan, an investigational therapy being developed for primary choroidal melanoma, a form of eye cancer. AU-011 is administered by intravitreal injection and is designed to target tumor cells in the eye before activating a light-based treatment intended to destroy them. The company is also advancing additional candidates based on its tumor-targeting technology for other solid tumors. Founded in 2009 and headquartered in the United States, Aura Biosciences conducts research and clinical development activities through collaborations and clinical programs in the U.S. and other regions. The company was founded and is led by Elisabet de los Pinos, who serves as president and chief executive officer.View Aura Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
